Fig. 2From: Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patientsReductions in target lesion diameters from baseline values per patientBack to article page